Vitamin  ||| S:0 E:8 ||| NNP
D  ||| S:8 E:10 ||| NNP
deficiency  ||| S:10 E:21 ||| NN
and  ||| S:21 E:25 ||| CC
primary  ||| S:25 E:33 ||| JJ
hyperparathyroidism  ||| S:33 E:53 ||| JJ
Vitamin  ||| S:53 E:61 ||| NNP
D  ||| S:61 E:63 ||| NNP
via  ||| S:63 E:67 ||| IN
its  ||| S:67 E:71 ||| PRP$
receptor  ||| S:71 E:80 ||| NN
has  ||| S:80 E:84 ||| VBZ
essential  ||| S:84 E:94 ||| JJ
actions  ||| S:94 E:102 ||| NNS
on  ||| S:102 E:105 ||| IN
parathyroid  ||| S:105 E:117 ||| JJ
cells ||| S:117 E:122 ||| NNS
,  ||| S:122 E:124 ||| ,
inhibiting  ||| S:124 E:135 ||| FW
PTH  ||| S:135 E:139 ||| FW
secretion ||| S:139 E:148 ||| FW
,  ||| S:148 E:150 ||| ,
and  ||| S:150 E:154 ||| CC
parathyroid  ||| S:154 E:166 ||| JJ
cell  ||| S:166 E:171 ||| NN
proliferation ||| S:171 E:184 ||| NN
.  ||| S:184 E:186 ||| .
While  ||| S:186 E:192 ||| IN
the  ||| S:192 E:196 ||| DT
effects  ||| S:196 E:204 ||| NNS
of  ||| S:204 E:207 ||| IN
vitamin  ||| S:207 E:215 ||| JJ
D  ||| S:215 E:217 ||| NNP
depletion  ||| S:217 E:227 ||| NN
in  ||| S:227 E:230 ||| IN
the  ||| S:230 E:234 ||| DT
pathogenesis  ||| S:234 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
secondary  ||| S:250 E:260 ||| JJ
hyperparathyroidism  ||| S:260 E:280 ||| NN
in  ||| S:280 E:283 ||| IN
elderly  ||| S:283 E:291 ||| JJ
individuals  ||| S:291 E:303 ||| NNS
or  ||| S:303 E:306 ||| CC
in  ||| S:306 E:309 ||| IN
the  ||| S:309 E:313 ||| DT
occurrence  ||| S:313 E:324 ||| NN
of  ||| S:324 E:327 ||| IN
parathyroid  ||| S:327 E:339 ||| JJ
hyperplasia  ||| S:339 E:351 ||| NN
in  ||| S:351 E:354 ||| IN
patients  ||| S:354 E:363 ||| NNS
with  ||| S:363 E:368 ||| IN
renal  ||| S:368 E:374 ||| JJ
insufficiency  ||| S:374 E:388 ||| NNS
are  ||| S:388 E:392 ||| VBP
well  ||| S:392 E:397 ||| RB
established ||| S:397 E:408 ||| VBN
,  ||| S:408 E:410 ||| ,
the  ||| S:410 E:414 ||| DT
association  ||| S:414 E:426 ||| NN
between  ||| S:426 E:434 ||| IN
hypovitaminosis  ||| S:434 E:450 ||| JJ
D  ||| S:450 E:452 ||| NNP
and  ||| S:452 E:456 ||| CC
primary  ||| S:456 E:464 ||| JJ
hyperparathyroidism  ||| S:464 E:484 ||| NNS
( ||| S:484 E:485 ||| -LRB-
P-HPT ||| S:485 E:490 ||| NNP
)  ||| S:490 E:492 ||| -RRB-
has  ||| S:492 E:496 ||| VBZ
only  ||| S:496 E:501 ||| RB
recently  ||| S:501 E:510 ||| RB
become  ||| S:510 E:517 ||| VB
appreciated ||| S:517 E:528 ||| VBN
.  ||| S:528 E:530 ||| .
In  ||| S:530 E:533 ||| IN
different  ||| S:533 E:543 ||| JJ
cohorts  ||| S:543 E:551 ||| NNS
of  ||| S:551 E:554 ||| IN
patients  ||| S:554 E:563 ||| NNS
with  ||| S:563 E:568 ||| IN
P-HPT ||| S:568 E:573 ||| NNP
,  ||| S:573 E:575 ||| ,
vitamin  ||| S:575 E:583 ||| VBG
D  ||| S:583 E:585 ||| NNP
deficiency  ||| S:585 E:596 ||| NN
has  ||| S:596 E:600 ||| VBZ
been  ||| S:600 E:605 ||| VBN
recently  ||| S:605 E:614 ||| RB
associated  ||| S:614 E:625 ||| VBN
with  ||| S:625 E:630 ||| IN
higher  ||| S:630 E:637 ||| JJR
PTH  ||| S:637 E:641 ||| NN
levels ||| S:641 E:647 ||| NNS
,  ||| S:647 E:649 ||| ,
larger  ||| S:649 E:656 ||| JJR
adenomas ||| S:656 E:664 ||| NN
,  ||| S:664 E:666 ||| ,
and  ||| S:666 E:670 ||| CC
a  ||| S:670 E:672 ||| DT
more  ||| S:672 E:677 ||| RBR
severe  ||| S:677 E:684 ||| JJ
phenotype  ||| S:684 E:694 ||| NNS
( ||| S:694 E:695 ||| -LRB-
including  ||| S:695 E:705 ||| FW
osteitis  ||| S:705 E:714 ||| FW
fibrosa  ||| S:714 E:722 ||| FW
cystica ||| S:722 E:729 ||| FW
)  ||| S:729 E:731 ||| -RRB-
as  ||| S:731 E:734 ||| IN
well  ||| S:734 E:739 ||| RB
as  ||| S:739 E:742 ||| IN
negative  ||| S:742 E:751 ||| JJ
post-operative  ||| S:751 E:766 ||| JJ
outcomes  ||| S:766 E:775 ||| NNS
following  ||| S:775 E:785 ||| VBG
parathyroidectomy ||| S:785 E:802 ||| NNS
.  ||| S:802 E:804 ||| .
Despite  ||| S:804 E:812 ||| IN
current  ||| S:812 E:820 ||| JJ
guidelines  ||| S:820 E:831 ||| NNS
recommend  ||| S:831 E:841 ||| VBP
measurement  ||| S:841 E:853 ||| VBN
of  ||| S:853 E:856 ||| IN
serum  ||| S:856 E:862 ||| CD
25OHD  ||| S:862 E:868 ||| CD
( ||| S:868 E:869 ||| -LRB-
25-hydroxy-cholecalciferol ||| S:869 E:895 ||| NNP
)  ||| S:895 E:897 ||| -RRB-
in  ||| S:897 E:900 ||| IN
P-HPT  ||| S:900 E:906 ||| JJ
and  ||| S:906 E:910 ||| CC
their  ||| S:910 E:916 ||| PRP$
repletion  ||| S:916 E:926 ||| NN
if  ||| S:926 E:929 ||| IN
the  ||| S:929 E:933 ||| DT
levels  ||| S:933 E:940 ||| NNS
are  ||| S:940 E:944 ||| VBP
< ||| S:944 E:945 ||| SYM
20  ||| S:945 E:948 ||| CD
ng ||| S:948 E:950 ||| CD
/ ||| S:950 E:951 ||| CD
ml ||| S:951 E:953 ||| NN
,  ||| S:953 E:955 ||| ,
future  ||| S:955 E:962 ||| JJ
well-designed  ||| S:962 E:976 ||| JJ
trials  ||| S:976 E:983 ||| NNS
of  ||| S:983 E:986 ||| IN
vitamin  ||| S:986 E:994 ||| JJ
D  ||| S:994 E:996 ||| NNP
supplementation  ||| S:996 E:1012 ||| NN
in  ||| S:1012 E:1015 ||| IN
P-HPT  ||| S:1015 E:1021 ||| JJ
patients  ||| S:1021 E:1030 ||| NNS
with  ||| S:1030 E:1035 ||| IN
coexisting  ||| S:1035 E:1046 ||| JJ
vitamin  ||| S:1046 E:1054 ||| JJ
D  ||| S:1054 E:1056 ||| NNP
deficiency  ||| S:1056 E:1067 ||| NNS
are  ||| S:1067 E:1071 ||| VBP
needed  ||| S:1071 E:1078 ||| VBN
to  ||| S:1078 E:1081 ||| TO
evaluate  ||| S:1081 E:1090 ||| VB
the  ||| S:1090 E:1094 ||| DT
risk ||| S:1094 E:1098 ||| NN
/ ||| S:1098 E:1099 ||| CD
benefit  ||| S:1099 E:1107 ||| NN
profile  ||| S:1107 E:1115 ||| NN
of  ||| S:1115 E:1118 ||| IN
this  ||| S:1118 E:1123 ||| DT
treatment ||| S:1123 E:1132 ||| NN
.  ||| S:1132 E:1134 ||| .
